Italy healthcare sector sees advancements in oncology and personalized medicine

Recent medical developments and policy discussions in Italy highlight a shift toward personalized medicine and multidisciplinary care. At the ESMO congress in Madrid, researchers from the Regina Elena National Cancer Institute presented studies showing that combining targeted pharmacological treatments with surgery can significantly improve survival rates for bladder and prostate cancers.

In the field of breast cancer, clinical studies such as Natalee are evaluating the use of cyclin inhibitors like ribociclib to reduce recurrence risks in high-risk patients. Additionally, new data from the OASIS-4 study suggests that elinzanetant can effectively reduce vasomotor symptoms, such as hot flashes, in women undergoing endocrine therapy.

On a systemic level, Italian President Sergio Mattarella has called for the elimination of territorial disparities in healthcare access, noting that economic and geographic barriers should not impede life-saving screenings and treatments. Meanwhile, experts are emphasizing the integration of genetics into diagnostic pathways to manage conditions like cardiac amyloidosis and the importance of monitoring the immune system to tailor treatments for multiple sclerosis.